Disease · MONDO_0005530
Comparisons in its trials82
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 82
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BNX Tablets, Then OL BNX Tablets, Then BNX Film vs Buprenorphine, Then OL BNX Film, Then BNX Tablets: serious adverse events | 3 of 383 | 1 of 375 | 758 | NCT01908842 | Trial comparisons |
| Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study | 336 of 371 | 53 of 65 | 436 | NCT01218997 | Trial comparisons |
| Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: serious adverse events | 49 of 371 | 5 of 65 | 436 | NCT01218997 | Trial comparisons |
Buprenorphine/Naloxone Film Strip Administered Sublingually vs Buprenorphine/Naloxone Film Strip Administered Buccally: Number of Subjects With Treatment-emergent Adverse Events Associated With the Oral Cavity. | 11 of 194 | 16 of 188 | 382 | NCT00640835 | Trial comparisons |
| Buprenorphine/Naloxone Film Strip Administered Sublingually vs Buprenorphine/Naloxone Film Strip Administered Buccally: serious adverse events | 4 of 194 | 2 of 188 | 382 | NCT00640835 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: Discontinuation Due to Experiencing an Adverse Event | 10 of 156 | 1 of 156 | 312 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: deaths from any cause | 0 of 156 | 0 of 156 | 312 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: serious adverse events | 0 of 156 | 0 of 156 | 312 | NCT03089983 | Trial comparisons |
| BNX Sublingual Tablets Induction vs Buprenorphine Induction: Retention in Treatment in the Full Analysis Population | 132 of 155 | 147 of 155 | 310 | NCT01848054 | Trial comparisons |
| BNX Sublingual Tablets Induction vs Buprenorphine Induction: serious adverse events | 1 of 155 | 2 of 155 | 310 | NCT01848054 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Adherence | 9 of 152 | 117 of 153 | 305 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Completion Rates in Prison | 114 of 152 | 127 of 153 | 305 | NCT03089983 | Trial comparisons |
| BNX Sublingual Tablets Induction vs Buprenorphine Induction: Retention in Treatment in the Per Protocol Population | 113 of 128 | 122 of 128 | 256 | NCT01848054 | Trial comparisons |
| VIVITROL® 380 mg vs Placebo: serious adverse events | 3 of 126 | 4 of 124 | 250 | NCT00678418 | Trial comparisons |
| Rapid Wean vs Slow Wean: deaths from any cause | 0 of 98 | 0 of 91 | 189 | NCT04214834 | Trial comparisons |
| Rapid Wean vs Slow Wean: serious adverse events | 1 of 98 | 1 of 91 | 189 | NCT04214834 | Trial comparisons |
| Direct Suboxone Induction vs Subutex-to-Suboxone Induction: serious adverse events | 1 of 93 | 3 of 94 | 187 | NCT00604188 | Trial comparisons |
| Buprenorphine Implants + Placebo Tablets vs Buprenorphine Tablets + Placebo Implants: serious adverse events | 2 of 87 | 3 of 89 | 176 | NCT02180659 | Trial comparisons |
| Computer Delivered CRA + CM + Suboxone vs CM + Suboxone: serious adverse events | 0 of 91 | 0 of 79 | 170 | NCT00929253 | Trial comparisons |
| Gabapentin vs Placebo: Detox Phase Completers | 41 of 60 | 34 of 57 | 117 | NCT02543944 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005530/comparisons